🏥Clinical Validation and Efficacy Studies

MEDai (MEDai) is committed to rigorous clinical validation and efficacy studies to demonstrate the effectiveness of its virtual reality therapy interventions in treating various mental health disorders. Through collaborative partnerships with academic institutions, research organizations, and healthcare providers, MEDai will conduct controlled trials, longitudinal studies, and real-world evaluations to assess the impact of its platform on user outcomes and well-being.

Key aspects of clinical validation and efficacy studies conducted by MEDai include:

• Study Design and Methodology: MEDai's AI-technology designs and implements studies using rigorous scientific methods and standardized assessment tools to measure treatment outcomes, symptom reduction, and functional improvement. Randomized controlled trials (RCTs), comparative effectiveness studies, and longitudinal follow-up assessments are conducted to evaluate the efficacy, safety, and cost-effectiveness of virtual reality therapy interventions.

• Target Populations and Disorders: MEDai's clinical studies target diverse populations and mental health disorders, including anxiety disorders, depression, PTSD, addiction, and neurodevelopmental disorders. By recruiting participants from clinical populations, community settings, and online platforms, MEDai aims to generate evidence that is generalizable, representative, and applicable to real-world practice.

• Outcome Measures and Assessment Tools: MEDai employs a variety of validated outcome measures and assessment tools to evaluate treatment response, symptom severity, and functional impairment. Measures such as the Beck Depression Inventory (BDI), State-Trait Anxiety Inventory (STAI), and Clinician-Administered PTSD Scale (CAPS) are used to assess changes in mood, anxiety, and trauma-related symptoms before and after therapy interventions.